We are developing a new class of therapeutics targeting the effects of disease-driving sRNA isoforms
DISCOVERY PIPELINE OF THERAPEUTIC PROGRAMS FOCUS ON AREAS WITH KNOWN HETEROGENEITY
Gatehouse Bio has used its Code-Breaker™ Platform to analyze multiple diseases and identify hotspots where there is high isoform burden. These hotspots have created a portfolio of novel drug targets, each of which has relevance across several diseases, creating the opportunity for deep pipeline growth. Gatehouse Bio is currently developing its lead targets into biomarker-guided precision therapies for the treatment of pulmonary, cardiac, neurological, and autoimmune diseases. Code-Breaker’s capabilities can be applied to the discovery and design of oligonucleotide therapeutics for a significantly broader range of diseases than the company’s initial focus areas.